Treatment with glucose-lowering agent(s) other than metformin in a period of 3 months prior to screening, previous use of insulin
Participants who usually did not eat breakfast
Type 1 diabetes mellitus
Body Mass Index (BMI) ≤ 20 kg/m\^2 and \> 40 kg/m\^2
Pregnancy or lactation, women of childbearing potential with no effective contraceptive method
Amylase and/or lipase \> 3 times the upper limit of the normal laboratory range ( ULN) at screening
Alanine aminotransferase (ALT) \> 3 ULN at screening
Calcitonin ≧ 20 pg/ml (5.9 pmol/L) at screening
History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy.
Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predisposes to MTC (e.g. multiple endocrine neoplasia syndromes)
Any contra-indication related to metformin
Any previous treatment with lixisenatide
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Clareo Health | Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
